Masimo (NASDAQ:MASI) announces that RD SET sensors with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry have received FDA clearance for improved oxygen saturation (SpO2) accuracy specifications for neonatal patients (<3 kg).
The updated RD SET sensors’ SpO2 accuracy specifications have improved significantly, from 3% to 1.5% ARMS (at 1 standard deviation), in conditions of motion and no motion.
Additionally, RD SET sensors are designed to enhance patient comfort, optimize clinician workflows, and help hospitals meet green initiatives.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.